GPCR
Structure·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
RSI Oversold
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GPCR
Structure Therapeutics Inc.
A biotech company developing oral small molecule therapies to treat various chronic diseases
Chemical and pharmaceutical
--
02/03/2023
NASDAQ Stock Exchange
220
12-31
Depository Receipts (Ordinary Shares)
601 Gateway Blvd., Suite 900, South San Francisco, California 94080
Develops oral small molecule therapeutics.
Sudi Bio was established in the Cayman Islands in February 2019 and has operating subsidiaries in the United States and China. The company is a clinical-stage global biopharmaceutical company that develops and delivers novel oral therapies to treat a variety of chronic diseases to meet medical needs. The Company's differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling the Company to develop oral small molecule therapies for the treatment of various diseases, including those affecting the metabolic, cardiovascular and pulmonary systems.
Company Financials
EPS
GPCR has released its 2026 Q2 earnings. EPS was reported at -0.44, versus the expected -0.41, missing expectations. The chart below visualizes how GPCR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
